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Prostate cancer is is the most common solid neoplasm and it is now recognized as one of the most important medical problems
facingthemalepopulation.Duetoitslonglatencyanditsidentiﬁablepreneoplasticlesions,prostatecancerisanidealtargettumor
for chemoprevention. Diﬀerent compounds are available and certainly polyphenols represent those with eﬃcacy against prostate
cancer. This review take a look at activity and properties of major polyphenolic substances, such as epigallocatechin-3-gallate,
curcumin, resveratrol and the ﬂavonoids quercetin and genistein. Although the current studies are limited, mechanisms of action
of polyphenols added with the lack of side eﬀects show a a start for future strategies in prostate chemoprevention.
1.Introduction
Chemoprevention is deﬁned as the use of speciﬁc natural
(dietary) or synthetic agents to prevent, delay, or slow the
carcinogenicprocess.Prostatecancerisanidealtargetdisease
for chemoprevention thanks to long latency, high incidence,
tumor marker availability (prostate-speciﬁc antigen, PSA),
identiﬁable preneoplastic lesions, and because it is a very
heterogeneous disease with a large subgroup of patients with
nonaggressive disease [1].
Up to now the two principal targets for prostate can-
cerchemopreventionhavebeeninﬂammationandhormonal
stimulation: between all prostate cancer risk reduction stud-
ies, the only ones who were successful are PCPT (ﬁnasteride)
and REDUCE (dutasteride).
Although most prostate cancers behave indolently and
are undiagnosed during life, it is still the second most com-
mon cause of cancer death in men and it will become a
considerable health problem in the next millennium, as the
adult population is increasing [1, 2].
The incidence and mortality of prostate cancer shows
strong variations worldwide with the highest rates in North
America, Australia, Western and Northern Europe and the
lowest rates in Japan and other Asian countries [1].
Thesewidevariationshavebeenexploredandnutritional
factors were found to play a role together with genetic,
behavioral, occupational, and environmental ones. Since
prostate cancer typically develops later in life, identifying
botanical compounds to prevent or delay disease progression
may have a positive eﬀect on quality of life and reduce
healthcare costs of the aging population [3].
According to the National Cancer Institute, about 400
compounds have been listed as potential chemopreventive
agents and about 40 of these are currently under clinical
evaluation. This paper systematically examines the data on
the prostate cancer chemopreventive action of polyphenols,
a class of diet constituents that showed notable eﬃcacy in
preclinical models of carcinogenesis, analyzing in particular
the mechanisms of action of some polyphenolic substances,
such as epigallocatechin-3-gallate, curcumin, resveratrol and
the ﬂavonoids quercetin and genistein (Table 1)[ 4].2 Oxidative Medicine and Cellular Longevity
Table 1: Summary of studies on polyphenols and their respective mechanisms of action.
Compound Type of study Cell culture system or
animal studies Concentration used Mechanisms of action
Epigallocatechin-3-
gallate
In vitro
[7, 8, 10]; in
vivo [9]; in
humans [12, 13]
LNCaP and PC-3 [8];
athymic nude mice [9];
LNCaP and DU-145 [7]
In vitro: 10–40
micromol/L [8]; in vivo:
EGCG (62%) [9]; in
humans: 600mg/d [12];
5 cups/day [13]
Activation of caspase-6
and -9 [8]; reduction of
expression of androgen
receptor [9]; inhibition of
(MMP-2 and -2) and
VEGF [10]
Curcumin
In vitro
[16, 19, 22–25];
in humans [28]
LNCaP [16, 20], DU145
and LNCaP [19]; LNCaP
[20]; L1210 mouse
leukemia cell line [22];
PC-3 and DU145 [23];
PC-3 [24]; DU-145 [25]
In vitro: 30μmol/L [16];
10μM[ 20]; 1–100μM
[19]; 0–45μM[ 22];
1–10μM[ 23]; 2–5μM
[24]; 10mg/mL [25]; in
humans: 0.4 to 3.6g [28]
Reduction of MDM2
protein and induction of
gene NKX3.1 [16];
induction of apoptosis
and the activation of
procaspase-3 and -8 [19]
and caspase-9 and -3 [24];
reduction of MMP-2 and
-9 [25]; decrease of PGE-2
[28]
Resveratrol In vitro [29, 30]
LNCaP, DU-145, PC-3
[29]; LNCaP and
DU-145 [30]
In vitro: 2–40μM[ 29];
1μmol [30]
Inhibition of the
formation of free radicals
[29] and induction of
apoptosis [30].
Quercetin In vitro [31–35]
PC-3 and LNCaP
[31, 35]; LNCaP [32];
PC-3 [33, 34]
In vitro: 20–40μM[ 31];
100 microM [32–35]; in
humans: 24μg[ 36]
Activation of caspase-9
and caspase-3 [31];
induction of apoptosis
[32, 33]; downregulation
of the expression of
MMP-2 and -9 [34];
suppression of androgen
receptor [35]
Genistein
In vitro:
[37–39]; in vivo:
[40]
LNCaP and PC-3 [37];
LNCaP, DU-145 and
PC-3 [38]; PC-3 [39].
In vitro: 10–20μM[ 37];
20μM[ 38]; 0–250μM
[39]i nh u m a n s :3 0m g
[41]
Inhibition of angiogenesis
and downregulation of
TGF-β and EGF [37, 42];
increase of the glutathione
peroxidase (GPx)-1 [38];
decrease of metastases by
96% [39]; serum prostate
speciﬁc antigen (PSA)
decreased by 7.8% [41]
2.Epigallocatechin-3-Gallate
Epigallocatechin-3-gallate (EGCG) represents the major
polyphenolic constituent present in green tea, the most pop-
ularbeveragenexttowater,thathaspotentialtobedeveloped
as a chemopreventive agent for prostate cancer (Figure 1).
The tea plant (Camellia sinensis) has been cultivated in Asia
for thousands of years, and Green tea has been used for
centuries in China, Japan, and Thailand as a traditional
medicine with a variety of applications [5].
Over the last two decades many epidemiological studies
have evaluated the chemopreventive properties of green tea,
suggesting that increasing intake of green tea is correlated
with signiﬁcant decrease in the development of prostate
cancer [6].
Due to its anticarcinogenic eﬀects, such as inhibition of
growth proliferation, induction of apoptosis, induction of
phase II detoxifying enzymes, and reduction of oxidative
damage to DNA, various in vitro and in vivo studies have
more speciﬁcally shown that consumption of green tea
polyphenols is associated with decreased risk and/or slower
progression of prostate cancer [5].
According to cell-culture studies, EGCG induced apop-
tosis and cell cycle arrest in many cancer cells without
aﬀecting normal cells. Particularly in prostate cancer cells,
EGCG activates growth arrest and apoptosis primarily via
p53-dependent pathway that involves the function of both
p21 and Bax such that downregulation of either molecule
confers a growth advantage to the cells. In androgen-
sensitive LNCaP and androgen-insensitive PC-3 human
prostate carcinoma cells, EGCG inhibited COX-2, (inducible
enzymaticisoform,rapidlyinducedbygrowthfactors,tumor
promoters, oncogenes, and carcinogens) without aﬀecting
COX-1 expression at both the mRNA and protein levels [7].
A study published in 2007 tested the eﬀect of epigal-
locatechin-3-gallate alone and in combination with speciﬁc
COX-2 inhibitors on the growth and apoptosis of human
prostate cancer cells both in vitro and in vivo. This studyOxidative Medicine and Cellular Longevity 3
HO O
O
O
OH
OH
OH
OH
OH
OH
OH
Figure 1: Epigallocatechin-3-gallate.
demonstrated a synergic action and an increased eﬃcacy of
selectiveCOX-2inhibitorsincombinationwithpolyphenols,
from green tea, for inhibition of growth of human prostate
cancercellsbothinvitroandinvivo.Itwasobservedthatthis
eﬀect was mainly due to increased apoptosis after increased
activation of caspase-6 and caspase-9 [8].
It has been shown that ester bond-containing tea
polyphenols, such as EGCG, potently and speciﬁcally inhibit
thechymotrypsin-likeactivityoftheproteasomeinvitroand
in vivo at the concentrations found in the serum of green tea
drinkers, causing growth arrest in the G(1) phase of the cell
cycle [7].
In a study published in 2006 the combination treatment
with EGCG, green tea extract, water extract of black tea, and
theaﬂavins was shown to reduce gene expression and protein
expression of androgen receptor in the athymic nude mice
implanted with androgen-sensitive human CaP CWR22Rν1
cells that resulted in induction of apoptosis, decrease in the
levels of VEGF protein, reduction in the level of serum PSA,
a n dar e d u c e dt u m o rv o l u m e[ 7, 9].
Furthermore, this polyphenolic compound seems to
inhibit tumor expression of matrix metalloproteases (MMP-
2 and MMP-9) and vascular endothelial growth factor
(VEGF), which are overexpressed in angiogenesis, and there-
by prevent the invasion and the metastatic spread of cancer
[10].
In a mouse model of orthotopic androgen-sensitive
human PCa, the combination of soy phytochemical concen-
trate, black tea, and green tea signiﬁcantly reduced tumori-
genicity. This association synergistically inhibited tumor
angiogenesis,ﬁnaltumorweight,metastasisandsigniﬁcantly
reduced serum concentrations of both testosterone and
dihydrotestosterone in vivo [11].
A prospective, double-blind, placebo-controlled study,
using a deﬁned product of green tea in capsule form in
men with HG-PIN, observed a 90% reduction in developing
Pca. This was the ﬁrst study that has shown the eﬀectiveness
of green tea polyphenols for the treatment of premalignant
lesions of prostate cancer [12].
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Figure 2: Curcumin.
In the Japan Public Health Center-based prospective
study, 49,950 men aged 40 to 69 completed a questionnaire
on the basis of their green tea consumption habit. Consump-
tion was associated with a dose-dependent decrease in the
risk of advanced PCa. The multivariate relative risk was 0.52
for men drinking 5 or more cups/day compared with less
than 1cup/day [13].
However, further studies are needed so that the EGCG
can be safely considered as chemopreventive agents for
prostate cancer.
3.Curcumin
Curcumin (diferuloylmethane) is a major chemical compo-
nent ofturmeric (CurcumalongaLinn.)andisusedasaspice
to give a speciﬁc ﬂavor and yellow color to food in the Indian
subcontinent (Figure 2)[ 14].
It has been used for centuries throughout Asia not only
as a food additive but also as cosmetic and as a traditional
herbalmedicinetotreatavarietyofinﬂammatoryconditions
and chronic diseases. Over the past decade, several studies
have substantiated the potential prophylactic or therapeutic
value of curcumin and have unequivocally supported reports
of its anticarcinogenic properties, such as its ability to
inﬂuence a diverse range of molecular targets within cells.
To date, no studies have reported any toxicity associated with
the use of curcumin in either animals or humans [15].
The chemopreventive properties of curcumin are
attributed to its eﬀect on several targets including
transcriptionfactors,growthregulators,adhesionmolecules,
apoptotic genes, angiogenesis regulators, and cellular
signaling molecules. It has been shown that curcumin has
the ability to induce apoptosis in both androgen-dependent
and androgen-independent prostate cancer cells acting
through the downregulating apoptosis suppressor proteins
and other crucial proteins such as the androgen receptor. In
PC-3 (hormone-independent line possessing dysfunctional
androgen receptors) and LNCaP (hormone-sensitive cells),
curcumin signiﬁcantly altered microﬁlament organization
and cell motility. In PC-3, human prostate cancer cell line,
curcumin reduced MDM2 protein and mRNA and enhanced
the expression of the tumor suppressor p21/WAF1, a gene
that encodes a potent cyclin-dependent kinase inhibitor of
cyclin-CDK2 and -CDK4 complexes, inducing apoptosis
and inhibiting proliferation.
Furthermore, curcumin inhibited androgen receptor-
mediated induction of NKX3.1 expression and decreased the4 Oxidative Medicine and Cellular Longevity
expression of androgen receptors and the binding activity to
antioxidant response element directly [16].
NKX3.1, a gene located nearly on 8p21.2, is involved
in the initiation stage of prostatic tumorigenesis. There
is considerable evidence that loss of NKX3.1 expression,
along with PTEN heterozygosity, a gene that codes for a
lipid phosphatase and functions as a negative regulator of
phosphoinositol-3-kinase (PI3K) signaling, is found at high
frequency in CaP [17].
NKX3.1 gene encodes a home-box-containing transcrip-
tion factor that functions as a negative regulator of epithelial
cell growth in prostate tissue. Thus, cellular NKX3.1 protein
levels are critical for maintenance of the prostate epithelial
phenotype. Experiments conducted on LNCaP and PC-3
cells demonstrated that inﬂammation and in particular over-
production of TNF-α and IL-β lead to rapid ubiquitination
and proteasomal degradation of NKX3.1 protein through
phosphorilation of serine-196 [18].
In a study, it was found that treatment of prostate cancer
cells with curcumin (1–100μM) suppresses both constitutive
(DU145) and inducible (LNCaP) NF-κB activation and
potentiates TNF-induced apoptosis. Curcumin treatment
(50–100μM) induced apoptosis in both cell types, which
correlatedwiththedownregulationoftheexpressionofBcl-2
and Bcl-xL and the activation of procaspase-3 and -8 [19].
A study also showed that curcumin blocks enhanced the
eﬀect of PSA expression by L-mimosine and dimethyloxalyl-
glycine, prolyl hydroxylase inhibitors, which induce hypoxia
condition [20].
In hormone refractory prostate cancer, it was found
that curcumin, in addition to conventional treatment, may
decrease prostate cancer aggressive proliferation and poten-
tiate activity of taxane therapy increasing cytotoxicity and
delaying prostate cancer cell resistance to these chemother-
apeutic drugs [21–23].
In combination with radiation, curcumin (2–5μM)
showed signiﬁcant enhancement of radiation-induced
clonogenic inhibition and apoptosis in PC-3 cells and
signiﬁcant activation of cytochrome c and caspases-9 and -3.
These mechanisms suggest that this natural compound acts
by overcoming the eﬀects of radiation-induced prosurvival
gene expression in prostate cancer [24].
Others in vitro and in vivo studies have also demon-
strated the inhibitory eﬀects exerted by treatment with only
curcumin against the growth and invasiveness of DU-145
prostate cancer cells. The inhibition of tumor cell invasion
was due to reductions in MMP-2 and MMP-9. Curcumin
was also shown to induce a marked reduction of tumor
volume. This compound may therefore have a role as
a chemopreventive agent and/or adjuvant therapy in the
treatment of prostate cancer, probably as a nontoxic dietary
supplement [25].
Until now, few clinical data about curcumin have been
performed in humans, despite the large amount of study
in vitro and in animals. For these reasons, it is not yet
known the pharmacokinetics properties of curcumin and its
eﬃcacious doses.
In a pilot study of a standardized oral Curcuma extract,
dosesupto180mgofcurcuminperdaywereadministeredto
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Figure 3: Resveratrol.
patients with advanced colorectal cancer for up to 4 months
without overt toxicity or detectable systemic bioavailability
[26]. A subsequent study has suggested that doses up to 8g
could be administered daily to patients with premalignant
lesions for 3 months without overt toxicity [27].
InaphaseIclinicaltrialoforalcurcumin,ﬁfteenpatients
with colorectal cancer refractory to standard chemotherapy
consumed a capsule with a dose escalation between 0.4g and
3.6g daily for up 4 months. A daily dose of 3.6g curcumin
engendered 62% and 57% decreases in inducible PGE-2,
suggesting a possible use of this compound for prevention
outside the gastrointestinal tract [28].
4. Resveratrol
Resveratrol (trans-3,4 ,5-trihydroxystilbene, C14H12O3)i sa
plant-derived polyphenolic phytoalexin produced by the
enzyme stilbene synthase in response to infection by the
pathogen Botrytis cinerea and to a variety of stress condi-
tions, such as vicissitudes in climate, exposure to ozone, sun-
light and heavy metals (Figure 3). It exists in two isoforms:
trans-resveratrol and cis-resveratrol where the transisomer is
the more stable form. Resveratrol is present in red grapes,
peanuts, some common drinks, and dietary supplements
[43].
It has broad-spectrum beneﬁcial health eﬀects including
anti-infective, antioxidant, and cardioprotective functions,
but it has gained considerable attention because of its
potential cancer chemopreventive properties [44]. In this
regard, resveratrol represents such an ideal molecule, due
to its relatively low toxicity and capacity to target multiple
signaling molecules that collectively promote cancer cell
survival and tumor growth. It was demonstrated that this
natural compound can modulate many intracellular cancer
targets, which aﬀect cell growth, inﬂammation, apoptosis,
angiogenesis, invasion and metastasis. It is also able to
potentiate the apoptotic eﬀects of cytokines, such as TRAIL,
chemotherapeutic agents, and gamma radiation [45].
Many in vitro studies have investigated the antiprolifera-
tive or proapoptotic eﬀects of resveratrol in human prostate
cancer cells, and its mechanism of action. Resveratrol was
found to inhibit the growth of LNCaP cells (hormone-
sensitive cells), DU-145 (androgen-independent cells), and
PC-3 (hormone-independent line possessing dysfunctional
androgen receptors) in a concentration-dependent manner.
It has also been shown to exert a strong inhibitory eﬀect
on the formation of free radicals in human macrophages,
reducing oxidative stress within premalignant cells, and toOxidative Medicine and Cellular Longevity 5
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Figure 4: Quercetin.
decrease the production of NO in PC-3 and DU-145 cells,
r e d u c i n gg r o w t ha n ds p r e a do fp r o s t a t ec a n c e r[ 29].
About its proapoptotic eﬀects, it has been shown to
induce apoptosis in LNCaP and DU145 prostate cancer
cell lines through diﬀerent PKC-mediated and MAPK-
dependent pathways [30].
Furthermore, resveratrol-mediated apoptosis has been
associated with p53 activation and also occurs via the death
receptor Fas/CD95/APO-1 in various human cancer cells
[45].
It is also possible that resveratrol exerts its chemopreven-
tive action in part by modulating the expression or function
of androgen receptor [29].
Another interesting chemopreventive mechanism related
with this compound is represented by sensitization eﬀect.
Research from in vitro and in vivo studies indicate that
resveratrol can overcome chemoresistance in tumor cells
by modulating apoptotic pathways, downregulating drug
transporters, downmodulating proteins involved in tumor
cell proliferation, and inhibiting NF-κB and STAT-3 pathway
[44].
Goldberg et al. reported that, after an oral dose of resver-
atrol (25mg/70kg), catechin (25mg/70kg), and quercetin
(10mg/70kg) to healthy human subjects, these compounds
appeared in serum and urine predominantly as glucuronide
and sulfate conjugates and free polyphenols accounted for
1.7–1.9% (resveratrol), 1.1 to 6.5% (catechin), and 17.2
to 26.9% (quercetin) of the peak serum concentrations
and more than 80% is absorbed. The absorption of trans-
resveratrol was the most eﬃc i e n ta sj u d g e db yp e a ks e r u m
concentration (16-17% of dose consumed) [46].
5. Quercetin
Quercetin is the main representative of the ﬂavonol class and
a polyphenolic antioxidant found in a variety of fruits and
vegetables, highly concentrated in onions, broccoli, apples,
grapes (red wine), and in soybeans (Figure 4).
This ﬂavonoid, besides having antioxidant and anti-
inﬂammatory activities, has been shown to possess potent
antiproliferative eﬀects against various malignant cells,
although its molecular mechanism involved in chemopre-
vention of prostate cancer remains unclear in many respects
[47]. Quercetin treatment has been associated with selective
antiproliferative eﬀects and induction of cell death, predom-
inantlythroughanapoptotic mechanism,incancercelllines.
Thiscompoundseemstobeabletoinduceapoptosisthrough
multiple mechanisms: causing arrest in the G1 phase of the
cell cycle or through interaction with cell cycle-regulated
proteins, like cyclin D1 and CDK4; releasing cytochrome c
andactivatingcaspase-9andcaspase-3;throughinhibitionof
PI3K,anenzymeinvolvedinthepivotalcellsurvivalpathway,
synergizing the eﬀect of ECGC [31].
Epidemiological studies and preliminary data have
shown that quercetin inhibits the onset/growth of prostate
cancer. It was noted that there is a 27% risk reduction for
prostate cancer for those who consume at least 24μgo f
quercetin a day [36].
In human prostate carcinoma LNCaP cells, quercetin
inhibited the PI3K/Akt pathway, suppressed the phospho-
rylation of Bad, proapoptotic Bcl-2 family member, and
subsequentlyalteredtheinteractionbetweenBcl-xLandBax,
leading to cytochrome c release, activation of caspases and
consequently apoptotic death [32].
It was also found that quercetin inhibits the proliferation
of PC-3 cells causing a signiﬁcant decrease in Cdc2/Cdk-1
and cyclin B1 protein expressions and increasing hypophos-
phorylated level of pRb and this may be attributed to
decreased expression of growth responsive genes and subse-
quent growth inhibition of PC-3 cells [33].
Another important chemopreventive activity of
quercetin might be to reduce the risk of prostate cancer
metastasis. Tumor invasion and metastasis represent a
multistep process that depends on the activity of many
proteins. Proteolytic degradation of the extracellular matrix
components is a central event of this process, primarily due
to the action of matrix metalloproteinases.
A study showed that this natural compound inhibits the
expression of MMP 2 and 9 in prostate cancer cells (PC-3).
As it has been detected that MMP-2 and 9 expressions were
regulated by MAP kinase signaling pathways and quercetin
is an inhibitor of several kinases including MAP kinases and
tyrosine kinases, it is reasonable to speculate that quercetin
might have downregulated the expression of MMP-2 and -9
through inhibition of protein kinases [34].
In addition, quercetin appears to have the ability to sup-
press the function of androgen receptor, pivotal molecule in
normal development of the prostate and in the development
and progression of prostate cancer. Quercetin-mediated
inhibition of the androgen receptor transcription activity in
prostate cancer cells may be caused, at least in part, by the
formation of a protein complex containing c-Jun, Sp1, and
androgenreceptor,butfurtherinvestigationwillbenecessary
to examine whether other factors are also involved in this
protein complex [35].
6. Genistein
Genistein (4 ,5,7-trihydroxyisoﬂavone), the predominant
isoﬂavone in human nutrition, is derived mainly from
soybeansbutalsofromotherlegumes,includingpeas,lentils,
or beans (Figure 5)[ 38].6 Oxidative Medicine and Cellular Longevity
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Genistein has many important health beneﬁts, such as
lowering the incidence of cardiovascular diseases, prevention
of osteoporosis, attenuation of postmenopausal problems,
reduction of body mass and fat tissue. It also has chemo-
preventive properties, and in particular genistein has been
shown to inhibit growth of both androgen-dependent and
-independent prostate cancer cells in vitro. Several mech-
anisms have been proposed for genistein anticarcinogenic
activity: inhibition of protein-tyrosine kinase, with the
result of alleviating the growth of cancer cells by inhibiting
PTK-mediated signaling mechanisms; inhibition of topoiso-
merases I and II and protein histidine kinase with antiprolif-
erative or proapoptotic eﬀects; antioxidant eﬀects, through
inhibition of the expression of stress response related genes;
inhibition of NF-κB and Akt signaling pathways, both of
which are important for cell survival; the inhibition of
angiogenesis; the downregulation of transforming growth
factor-beta (TGF-β), and the inhibition of epidermal growth
factor (EGF) [37, 42].
In vitro studies have also demonstrated that this natural
compounddownregulatestheandrogenreceptorofPCacells
via the estrogen receptor β, resulting in a modiﬁed response
to hormonal stimuli, inhibits several steroid-metabolizing
e n z y m e ss u c ha s5 - α-reductase or aromatase creating a more
favorable hormonal milieu and a protective eﬀect against
prostate cancer, blocks the cell cycle progression at G1,a n d
inhibits PSA expression [38].
With regard to its antioxidant activity, a study examined
the eﬀect of genistein on human prostate cancer (LNCaP
and PC-3) cells. To obtain the gene expression proﬁle of
genistein in LNCaP cells, it was performed cDNA microarray
analysis. This survey has shown that while the expression of
many genes, including apoptosis inhibitor (survivin), DNA
topoisomerase II, cell division cycle 6 (CDC6), and mitogen-
activated protein kinase 6 (MAPK 6), was downregulated,
the glutathione peroxidase (GPx)-1 gene expression level
was upregulated with a subsequent increase of GPx enzyme
activities.
Thetumorinitiationandprogressionareoftenattributed
to oxidative stress and the generation of ROS, which exceed
cell ability of metabolize and detoxify them.
In addition to causing genetic changes, ROS may lead to
epigenetic alterations that aﬀect the genome and play a key
role in the development of human carcinogenesis [40].
More speciﬁcally, ROS production is associated with
alterations in DNA methylation patterns.
Furthermore, ROS-induced oxidative stress can con-
tribute to gene silencing by mechanisms that involve aber-
rant hypermethylation of tumor suppressor gene promoter
regions and thus lead towards progression to a malignant
phenotype [48].
OxygenradicalsmaycausedamagetoDNAandchromo-
somes,induceepigeneticalterations,interactwithoncogenes
or tumor suppressor genes, and impart changes in immuno-
logical mechanisms, like mutation of nuclear encoded genes
such as TP53, promotes carcinogenesis [49, 50].
ROS are further determinant for the activation of
inﬂammatory pathways that play a key role in cancer pro-
gression. Inﬂammation in cancer involves a close interplay
between tumor-associated immune cells and the tumor cells
themselves. Activation of NF-κB and AP-1 in immune cells,
induced by ROS, determines production of inﬂammatory
cytokines such as TNFα a n dI L - 6t h a th a v eb e e nd e m o n -
strated to be important in tumor progression [51].
Since ROS are considered key participants in the pro-
gression cancer, the antioxidant eﬀect of genistein might
prevent tumor invasion or metastasis in prostate cancer
cells inhibiting production of matrix metalloproteinase, cell
motility and degradation of the basement membrane. [52].
The antimetastatic potential of genistein was evaluated
by a study through the development of an animal model,
a murine model of human PCa metastasis. It has been
demonstrated that genistein inhibits initial steps in the
metastaticcascade,namely,celldetachmentandcellinvasion
and for the ﬁrst time induces ﬂattening of cell nuclei in vivo,
a measure of increased cell attachment. Furthermore, genis-
tein, through inhibition of phosphorylation, has been shown
to inhibit activation of p38 MAPK and FAK (promotility
proteins) in vivo, blocking cell motility. Genistein decreased
metastases by 96%, induced nuclear morphometric changes
in PC3-M cells indicative of increased adhesion (i.e.,
decreased detachment) but did not alter tumor growth. This
study showed for the ﬁrst time that dietary concentrations of
genisteincaninhibitprostatecancercellmetastasis,butmore
speciﬁcanalysisonthegenisteineﬀectsuponhumanprostate
cells needed [39].
Another interesting study has investigated the potential
additive and synergistic eﬀects of genistein and resveratrol
for suppressing prostate cancer in the Simian Virus-40 T-
antigen (SV-40 Tag) targeted probasin promoter rat model,
a transgenic model of spontaneously developing prostate
cancer.Ithasbeenshownthathighdosegenisteinandresver-
atrol treatments, reducing cell proliferation and increasing
apoptosis mainly through the modulation of sex steroid
receptor and growth factor signaling, suppress the most
severe grade of prostate cancer in these transgenic animals
[53].
Inarandomized,placebo-controlled,double-blindphase
II clinical trial, ﬁfty-four study subjects were recruited and
randomized to treatment with genistein 30mg (n = 23)
or placebo (n = 24) for 3 to 6wk prior to prostatectomy.
Serum prostate speciﬁc antigen (PSA) decreased by 7.8% in
the genistein arm and increased by 4.4% in the placebo arm,
without adverse events and with beneﬁcial eﬀect on blood
cholesterol [41].Oxidative Medicine and Cellular Longevity 7
7. Conclusions
Since prostate cancer is one of the most important med-
ical problems aﬄicting male population, chemoprevention
strategies represent a promising approach to reduce the
incidence and mortality of this. Unfortunately, scientiﬁc
evidences about polyphenols should be still demonstrated
and well-conducted clinical studies are needed to clarify the
eﬃcacy of these molecules on prevention of PCa.
It should be better regulated the wide use of diﬀerent
dietary agents; in fact, being extractive products and not
synthetic products, they may elicit a great variability of
therapeutic results.
Among all mechanisms of action, these compounds have
shown antioxidant eﬀects by similar molecular pathways,
indicating a possible use of the associations of these polyphe-
nols, but few results have been developed.
Although a large amount of studies in vitro have been
conducted until now, few clinical trials, using precise con-
centrations of these compounds, have been performed. For
thesereasons,weencouragetoconductfurtherinvestigations
and more extensive studies to obtain conclusive evidences.
Despite all, diﬀerent biomolecular mechanisms of action
are promising, suggesting a real application in prostate
cancer prevention. Inhibition of angiogenesis, induction
of apoptosis, and reduction of tumor volume represent
a start for future strategies in prostate chemoprevention,
and understanding the underlying mechanisms of action,
especially on humans, may change the natural history of this
tumor.
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